PDF herunterladen
CC BY-NC-ND 4.0 · Thromb Haemost 2020; 120(10): 1357-1370
DOI: 10.1055/s-0040-1714279
Review Article

Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A

Georg Gelbenegger
1   Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
,
Christian Schoergenhofer
1   Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
,
Paul Knoebl
2   Division of Hematology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
,
Bernd Jilma
1   Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
› Institutsangaben Funding G.G. is supported by grant SFB54-P04 from the Austrian Science Funds.
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Hemophilia A, characterized by absent or ineffective coagulation factor VIII (FVIII), is a serious bleeding disorder that entails severe and potentially life-threatening bleeding events. Current standard therapy still involves replacement of FVIII, but is often complicated by the occurrence of neutralizing alloantibodies (inhibitors). Management of patients with inhibitors is challenging and necessitates immune tolerance induction for inhibitor eradication and the use of bypassing agents (activated prothrombin complex concentrates or recombinant activated factor VII), which are expensive and not always effective. Emicizumab is the first humanized bispecific monoclonal therapeutic antibody designed to replace the hemostatic function of activated FVIII by bridging activated factor IX and factor X (FX) to activate FX and allow the coagulation cascade to continue. In the majority of hemophilic patients with and without inhibitors, emicizumab reduced the annualized bleeding rate to almost zero in several clinical trials and demonstrated a good safety profile. However, the concurrent use of emicizumab and activated prothrombin complex concentrate imposes a high risk of thrombotic microangiopathy and thromboembolic events on patients and should be avoided. Yet, the management of breakthrough bleeds and surgery remains challenging with only limited evidence-based recommendations being available. This review summarizes published clinical trials and preliminary reports of emicizumab and discusses the clinical implications of emicizumab in treatment of hemophilia A.

Keywords

hemophilia - emicizumab - bleeding - bispecific antibody - coagulation


Publikationsverlauf

Eingereicht: 23. Februar 2020

Angenommen: 08. Juni 2020

Artikel online veröffentlicht:
27. Juli 2020

© 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Stuttgart · New York

 

  • References

  • 1 Soucie JM, Evatt B, Jackson D. ; The Hemophilia Surveillance System Project Investigators. Occurrence of hemophilia in the United States. Am J Hematol 1998; 59 (04) 288-294
    CrossrefPubMedGoogle Scholar
  • 2 Srivastava A, Brewer AK, Mauser-Bunschoten EP. , et al; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19 (01) e1-e47
    CrossrefPubMedGoogle Scholar
  • 3 Mannucci PM, Tuddenham EG. The hemophilias--from royal genes to gene therapy. N Engl J Med 2001; 344 (23) 1773-1779
    CrossrefPubMedGoogle Scholar
  • 4 Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A. ; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12 (11) 1935-1939
    CrossrefPubMedGoogle Scholar
  • 5 Franchini M, Favaloro EJ, Lippi G. Mild hemophilia A. J Thromb Haemost 2010; 8 (03) 421-432
    CrossrefPubMedGoogle Scholar
  • 6 Carcao MD. The diagnosis and management of congenital hemophilia. Semin Thromb Hemost 2012; 38 (07) 727-734
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 7 Weyand AC, Pipe SW. New therapies for hemophilia. Blood 2019; 133 (05) 389-398
    CrossrefPubMedGoogle Scholar
  • 8 Franchini M, Mannucci PM. Hemophilia A in the third millennium. Blood Rev 2013; 27 (04) 179-184
    CrossrefPubMedGoogle Scholar
  • 9 Kuijlaars IAR, Timmer MA, de Kleijn P, Pisters MF, Fischer K. Monitoring joint health in haemophilia: Factors associated with deterioration. Haemophilia 2017; 23 (06) 934-940
    CrossrefPubMedGoogle Scholar
  • 10 Jansen NW, Roosendaal G, Lafeber FP. Understanding haemophilic arthropathy: an exploration of current open issues. Br J Haematol 2008; 143 (05) 632-640
    CrossrefPubMedGoogle Scholar
  • 11 Wheeler AP, Gailani D. The intrinsic pathway of coagulation as a target for antithrombotic therapy. Hematol Oncol Clin North Am 2016; 30 (05) 1099-1114
    CrossrefPubMedGoogle Scholar
  • 12 Baker CJ, Smith SA, Morrissey JH. Polyphosphate in thrombosis, hemostasis, and inflammation. Res Pract Thromb Haemost 2018; 3 (01) 18-25
    CrossrefPubMedGoogle Scholar
  • 13 Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998; 92 (11) 3983-3996
    CrossrefPubMedGoogle Scholar
  • 14 Kamikubo Y, Mendolicchio GL, Zampolli A. , et al. Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex. Blood 2017; 130 (14) 1661-1670
    CrossrefPubMedGoogle Scholar
  • 15 Gale AJ. Continuing education course #2: current understanding of hemostasis. Toxicol Pathol 2011; 39 (01) 273-280
    CrossrefPubMedGoogle Scholar
  • 16 Aledort L, Mannucci PM, Schramm W, Tarantino M. Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfus 2019; 17 (06) 479-486
    PubMedGoogle Scholar
  • 17 Mannucci PM. Benefits and limitations of extended plasma half-life factor VIII products in hemophilia A. Expert Opin Investig Drugs 2020; 29 (03) 303-309
    CrossrefPubMedGoogle Scholar
  • 18 Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood 2015; 125 (13) 2038-2044
    CrossrefPubMedGoogle Scholar
  • 19 Fischer K, van der Bom JG, Molho P. , et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002; 8 (06) 745-752
    CrossrefPubMedGoogle Scholar
  • 20 Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM. ; ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9 (04) 700-710
    CrossrefPubMedGoogle Scholar
  • 21 Manco-Johnson MJ, Abshire TC, Shapiro AD. , et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357 (06) 535-544
    CrossrefPubMedGoogle Scholar
  • 22 Manco-Johnson MJ, Soucie JM, Gill JC. ; Joint Outcomes Committee of the Universal Data Collection, US Hemophilia Treatment Center Network. Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. Blood 2017; 129 (17) 2368-2374
    CrossrefPubMedGoogle Scholar
  • 23 Aledort LM, Haschmeyer RH, Pettersson H. ; The Orthopaedic Outcome Study Group. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. J Intern Med 1994; 236 (04) 391-399
    CrossrefPubMedGoogle Scholar
  • 24 Santagostino E, Young G, Carcao M, Mannucci PM, Halimeh S, Austin S. A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies. Expert Rev Hematol 2018; 11 (02) 87-97
    CrossrefPubMedGoogle Scholar
  • 25 Collins PW, Fischer K, Morfini M, Blanchette VS, Björkman S. ; International Prophylaxis Study Group Pharmacokinetics Expert Working Group. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17 (01) 2-10
    CrossrefPubMedGoogle Scholar
  • 26 Troisi CL, Hollinger FB, Hoots WK. , et al. A multicenter study of viral hepatitis in a United States hemophilic population. Blood 1993; 81 (02) 412-418
    CrossrefPubMedGoogle Scholar
  • 27 Kumar A, Kulkarni R, Murray DL. , et al. Serologic markers of viral hepatitis A, B, C, and D in patients with hemophilia. J Med Virol 1993; 41 (03) 205-209
    CrossrefPubMedGoogle Scholar
  • 28 Kroner BL, Rosenberg PS, Aledort LM, Alvord WG, Goedert JJ. HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990. Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr (1988) 1994; 7 (03) 279-286
    PubMedGoogle Scholar
  • 29 Soucie JM, Richardson LC, Evatt BL. , et al; Hemophilia Surveillance System Project Investigators. Risk factors for infection with HBV and HCV in a largecohort of hemophiliac males. Transfusion 2001; 41 (03) 338-343
    CrossrefPubMedGoogle Scholar
  • 30 Arnold DM, Julian JA, Walker IR. ; Association of Hemophilia Clinic Directors of Canada. Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21 years of follow-up. Blood 2006; 108 (02) 460-464
    CrossrefPubMedGoogle Scholar
  • 31 Walsh CE, Soucie JM, Miller CH. ; United States Hemophilia Treatment Center Network. Impact of inhibitors on hemophilia A mortality in the United States. Am J Hematol 2015; 90 (05) 400-405
    CrossrefPubMedGoogle Scholar
  • 32 Monahan PE, Baker JR, Riske B, Soucie JM. Physical functioning in boys with hemophilia in the U.S. Am J Prev Med 2011; 41 (06) (Suppl. 04) S360-S368
    CrossrefPubMedGoogle Scholar
  • 33 Morfini M. Articular status of haemophilia patients with inhibitors. Haemophilia 2008; 14 (Suppl. 06) 20-22
    CrossrefPubMedGoogle Scholar
  • 34 Brown TM, Lee WC, Joshi AV, Pashos CL. Health-related quality of life and productivity impact in haemophilia patients with inhibitors. Haemophilia 2009; 15 (04) 911-917
    CrossrefPubMedGoogle Scholar
  • 35 Guh S, Grosse SD, McAlister S, Kessler CM, Soucie JM. Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008. Haemophilia 2012; 18 (02) 268-275
    CrossrefPubMedGoogle Scholar
  • 36 Ullman M, Hoots WK. Assessing the costs for clinical care of patients with high-responding factor VIII and IX inhibitors. Haemophilia 2006; 12 (Suppl. 06) 74-79
    CrossrefPubMedGoogle Scholar
  • 37 Kulkarni R, Aledort LM, Berntorp E. , et al. Therapeutic choices for patients with hemophilia and high-titer inhibitors. Am J Hematol 2001; 67 (04) 240-246
    CrossrefPubMedGoogle Scholar
  • 38 Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol 2013; 4 (01) 59-72
    CrossrefPubMedGoogle Scholar
  • 39 Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol 2004; 77 (02) 187-193
    CrossrefPubMedGoogle Scholar
  • 40 Dimichele D, Rivard G, Hay C, Antunes S. Inhibitors in haemophilia: clinical aspects. Haemophilia 2004; 10 (Suppl. 04) 140-145
    CrossrefPubMedGoogle Scholar
  • 41 Hay CR, DiMichele DM. ; International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119 (06) 1335-1344
    CrossrefPubMedGoogle Scholar
  • 42 Mariani G, Siragusa S, Kroner BL. Immune tolerance induction in hemophilia A: a review. Semin Thromb Hemost 2003; 29 (01) 69-76
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 43 Waters B, Lillicrap D. The molecular mechanisms of immunomodulation and tolerance induction to factor VIII. J Thromb Haemost 2009; 7 (09) 1446-1456
    CrossrefPubMedGoogle Scholar
  • 44 Gringeri A, Mantovani LG, Scalone L, Mannucci PM. ; COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102 (07) 2358-2363
    CrossrefPubMedGoogle Scholar
  • 45 Cafuir LA, Kempton CL. Current and emerging factor VIII replacement products for hemophilia A. Ther Adv Hematol 2017; 8 (10) 303-313
    CrossrefPubMedGoogle Scholar
  • 46 European Medicines Agency. Assessment report: Hemlibra. January 25, 2018. Available at: https://www.ema.europa.eu/en/documents/assessment-report/hemlibra-epar-public-assessment-report_en.pdf . Accessed June 26, 2020
    PubMedGoogle Scholar
  • 47 Kitazawa T, Igawa T, Sampei Z. , et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012; 18 (10) 1570-1574
    CrossrefPubMedGoogle Scholar
  • 48 Kitazawa T, Esaki K, Tachibana T. , et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost 2017; 117 (07) 1348-1357
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 49 Lenting PJ, Denis CV, Christophe OD. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?. Blood 2017; 130 (23) 2463-2468
    CrossrefPubMedGoogle Scholar
  • 50 Blair HA. Emicizumab: a review in haemophilia A. Drugs 2019; 79 (15) 1697-1707
    CrossrefPubMedGoogle Scholar
  • 51 Uchida N, Sambe T, Yoneyama K. , et al. A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood 2016; 127 (13) 1633-1641
    CrossrefPubMedGoogle Scholar
  • 52 Shima M, Hanabusa H, Taki M. , et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med 2016; 374 (21) 2044-2053
    CrossrefPubMedGoogle Scholar
  • 53 Pipe SW, Shima M, Lehle M. , et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol 2019; 6 (06) e295-e305
    CrossrefPubMedGoogle Scholar
  • 54 F. Hoffmann-La Roche Ltd. Investigator's Brochure: Emicizumab. November 2017
    PubMed
  • 55 Mahlangu J, Oldenburg J, Paz-Priel I. , et al. Emicizumab prophylaxis in patients who have hemophilia a without inhibitors. N Engl J Med 2018; 379 (09) 811-822
    CrossrefPubMedGoogle Scholar
  • 56 Oldenburg J, Mahlangu JN, Kim B. , et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377 (09) 809-818
    CrossrefPubMedGoogle Scholar
  • 57 Young G, Liesner R, Chang T. , et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood 2019; 134 (24) 2127-2138
    CrossrefPubMedGoogle Scholar
  • 58 Genentech Inc.. Hemlibra® (emicizumab-kxwh) injection, for subcutaneous use: US prescribing information. Available at: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2483adba-fab6-4d1b-96c5-c195577ed071 . Published 2018. Accessed October 14, 2019
    PubMedGoogle Scholar
  • 59 Callaghan M, Negrier C, Paz-Priel I. , et al. Emicizumab treatment is efficacious and well tolerated long term in persons with haemophilia A (PwHA) with or without FVIII inhibitors: pooled data from four HAVEN studies. Paper presented at: ISTH Congress 2019, Melbourne, Australia; July 6–10, 2019
    PubMedGoogle Scholar
  • 60 Shima M, Nogami K, Nagami S. , et al. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors. Haemophilia 2019; 25 (06) 979-987
    CrossrefPubMedGoogle Scholar
  • 61 Jiménez-Yuste V, Klamroth R, Castaman G. , et al. A single-arm, multicentre, open-label, phase III clinical trial to evaluate the safety and tolerability of prophylactic emicizumab in persons with haemophilia A (PwHA) with FVIII inhibitors (STASEY): interim analysis results. Paper presented at: ISTH Congress 2019, Melbourne, Australia; July 6–10, 2019
    PubMedGoogle Scholar
  • 62 Ebbert PT, Xavier F, Seaman CD, Ragni MV. Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors. Haemophilia 2020; 26 (01) 41-46
    CrossrefPubMedGoogle Scholar
  • 63 Santagostino E, Oldenburg J, Chang T. , et al. Surgical experience from four phase III studies (HAVEN 1-4) of emicizumab in persons with haemophilia A (PwHA) with or without FVIII inhibitors. Paper presented at: ISTH Congress 2019, Melbourne, Australia; July 6–10, 2019
    PubMedGoogle Scholar
  • 64 Seaman CD, Ragni MV. Emicizumab use in major orthopedic surgery. Blood Adv 2019; 3 (11) 1722-1724
    CrossrefPubMedGoogle Scholar
  • 65 Biron-Andreani CD-CI, Navarro R, Garcia-Gournay C, Theron A, Santagostino E, Schved J-F. Management of surgery in hemophilia A patients with inhibitors during emicizumab prophylaxis. Paper presented at: ISTH Congress 2019, Melbourne, Australia; July 6–10, 2019
    PubMedGoogle Scholar
  • 66 Dane KE, Lindsley JP, Streiff MB, Moliterno AR, Khalid MK, Shanbhag S. Successful use of emicizumab in a patient with refractory acquired hemophilia A and acute coronary syndrome requiring percutaneous coronary intervention. Res Pract Thromb Haemost 2019; 3 (03) 420-423
    CrossrefPubMedGoogle Scholar
  • 67 Oldenburg J, Mahlangu JN, Bujan W. , et al. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia 2019; 25 (01) 33-44
    CrossrefPubMedGoogle Scholar
  • 68 Müller J, Pekrul I, Pötzsch B, Berning B, Oldenburg J, Spannagl M. Laboratory monitoring in emicizumab-treated persons with hemophilia A. Thromb Haemost 2019; 119 (09) 1384-1393
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 69 Adamkewicz JI, Chen DC, Paz-Priel I. Effects and interferences of emicizumab, a humanised bispecific antibody mimicking activated factor VIII cofactor function, on coagulation assays. Thromb Haemost 2019; 119 (07) 1084-1093
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 70 Calatzis AKN, Levy G, Adamkewicz J. Effect of emicizumab – a humanized bispecific antibody mimicking FVIII cofactor function – on a variety of assay systems. Paper presented at: 2016 European Congress on Thrombosis and Haemostasis, Hague, Netherlands; 28–30 September, 2016
    PubMedGoogle Scholar
  • 71 Calhoon W, McInerney M, Calatzis A, Chen DC, Adamkewicz J, Morris M. Evaluation of a dedicated calibrator and controls for emicizumab quantification. Paper presented at: THSNA 2018, San Diego, California, United States; March 8–10, 2018
    PubMedGoogle Scholar
  • 72 Jenkins PV, Bowyer A, Burgess C. , et al. Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline. Haemophilia 2020; 26 (01) 151-155
    CrossrefPubMedGoogle Scholar
  • 73 Adamkewicz J, Soeda T, Kotani N, Calatzis A, Levy G. Effect of emicizumab (ACE910) – a humanized bispecific antibody mimicking FVIIIa cofactor function – on coagulation assays commonly in use for monitoring of hemophilia A patients. Paper presented at: 2017 Scientific Symposium of the Hemostasis and Thrombosis Research Society (HTRS), April 6–8, 2017; Scottsdale, AZ, United States
    PubMedGoogle Scholar
  • 74 Yada K, Nogami K, Kasai R, Shima M. A novel hemostatic monitoring system convertible to FVIII activity based on non-activated ROTEM (NATEM) for hemophilia A patients during emicizumab prophylaxis. 2018; 132 (Suppl. 01) 3782
    PubMedGoogle Scholar
  • 75 Hartmann R, Feenstra T, Valentino L, Dockal M, Scheiflinger F. In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents. J Thromb Haemost 2018
    PubMedGoogle Scholar
  • 76 Nogami K, Matsumoto T, Tabuchi Y. , et al. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab. J Thromb Haemost 2018; 16 (06) 1078-1088
    CrossrefPubMedGoogle Scholar
  • 77 Schmitt C, Adamkewicz JI, Xu J. , et al. Pharmacokinetics (PK), pharmacodynamics (PD), and PK/PD relationships of emicizumab in persons with hemophilia A (PwHA) with inhibitors from adolescent/adult (HAVEN 1) and paediatric (HAVEN 2) phase 3 studies. Paper presented at: 11th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), February 7–9, 2018 ; Madrid, Spain
    PubMedGoogle Scholar
  • 78 Dargaud Y, Lienhart A, Janbain M, Le Quellec S, Enjolras N, Negrier C. Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab. Haematologica 2018; 103 (04) e181-e183
    CrossrefPubMedGoogle Scholar
  • 79 Levy GG, Asikanius E, Kuebler P, Benchikh El Fegoun S, Esbjerg S, Seremetis S. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: experience from the HAVEN clinical program. J Thromb Haemost 2019; 17 (09) 1470-1477
    CrossrefPubMedGoogle Scholar
  • 80 Collins PW, Liesner R, Makris M. , et al. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee. Haemophilia 2018; 24 (03) 344-347
    CrossrefPubMedGoogle Scholar
  • 81 Susen S, Gruel Y, Godier A. , et al. Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra® ): proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP). Haemophilia 2019; 25 (05) 731-737
    CrossrefPubMedGoogle Scholar
  • 82 Castaman G, Santoro C, Coppola A. , et al. ad hoc Working Group. Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Blood Transfus 2020; 18 (02) 143-151
    PubMedGoogle Scholar
  • 83 Makris M, Iorio A, Lenting PJ. Emicizumab and thrombosis: The story so far. J Thromb Haemost 2019; 17 (08) 1269-1272
    CrossrefPubMedGoogle Scholar
  • 84 W Keith Hoots ADS. Treatment of bleeding and perioperative management in hemophilia A and B. Available at: https://www.uptodate.com/contents/treatment-of-bleeding-and-perioperative-management-in-hemophilia-a-and-b?search=hemophilia&source=search_result&selectedTitle=3~150&usage_type=default&display_rank=3#H2996978111 . Published 2020. Accessed February 13, 2020
    PubMedGoogle Scholar
  • 85 Hermans C, Astermark J, De Moerloose P. Exposure to factor VIII and prediction of inhibitor development: exposure days vs. danger days, or both?. J Thromb Haemost 2012; 10 (10) 2194-2196
    CrossrefPubMedGoogle Scholar
  • 86 Benson G, Auerswald G, Dolan G. , et al. Diagnosis and care of patients with mild haemophilia: practical recommendations for clinical management. Blood Transfus 2018; 16 (06) 535-544
    Google Scholar
  • 87 Eckhardt CL, van Velzen AS, Peters M. , et al; INSIGHT Study Group. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood 2013; 122 (11) 1954-1962
    CrossrefPubMedGoogle Scholar
  • 88 Kenet G, Barg AA, Nowak-Göttl U. Hemostasis in the very young. Semin Thromb Hemost 2018; 44 (07) 617-623
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 89 Barg AA, Avishai E, Budnik I. , et al. Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort. Pediatr Blood Cancer 2019; 66 (11) e27886
    CrossrefPubMedGoogle Scholar
  • 90 Temrikar ZH, Suryawanshi S, Meibohm B. Pharmacokinetics and clinical pharmacology of monoclonal antibodies in pediatric patients. Paediatr Drugs 2020; 22 (02) 199-216
    CrossrefPubMedGoogle Scholar
  • 91 Young G. Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after tolerance. Blood Adv 2018; 2 (20) 2780-2782
    CrossrefPubMedGoogle Scholar
  • 92 Aledort LM. Deaths associated with emicizumab in patients with hemophilia A. N Engl J Med 2019; 381 (19) 1878-1879
    CrossrefPubMedGoogle Scholar
  • 93 Ljung R, Auerswald G, Benson G. , et al. Inhibitors in haemophilia A and B: management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients. Eur J Haematol 2019; 102 (02) 111-122
    CrossrefPubMedGoogle Scholar
  • 94 Ettingshausen CE, Kreuz W. The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture?. Haemophilia 2013; 19 (Suppl. 01) 12-17
    CrossrefPubMedGoogle Scholar
  • 95 Batsuli G, Zimowski KL, Tickle K, Meeks SL, Sidonio Jr RF. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis. Haemophilia 2019; 25 (05) 789-796
    CrossrefPubMedGoogle Scholar
  • 96 Carcao M, Escuriola-Ettingshausen C, Santagostino E. , et al; Future of Immunotolerance Treatment Group. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia 2019; 25 (04) 676-684
    CrossrefPubMedGoogle Scholar
  • 97 Yoneyama K, Schmitt C, Kotani N. , et al. A pharmacometric approach to substitute for a conventional dose-finding study in rare diseases: example of phase III dose selection for emicizumab in hemophilia A. Clin Pharmacokinet 2018; 57 (09) 1123-1134
    CrossrefPubMedGoogle Scholar
  • 98 Al-Banaa K, Alhillan A, Hawa F. , et al. Emicizumab use in treatment of acquired hemophilia A: a case report. Am J Case Rep 2019; 20: 1046-1048
    CrossrefPubMedGoogle Scholar
  • 99 Möhnle P, Pekrul I, Spannagl M, Sturm A, Singh D, Dechant C. Emicizumab in the treatment of acquired haemophilia: a case report. Transfus Med Hemother 2019; 46 (02) 121-123
    CrossrefPubMedGoogle Scholar
  • 100 Knöbl P. Prevention and management of bleeding episodes in patients with acquired hemophilia A. Drugs 2018; 78 (18) 1861-1872
    CrossrefPubMedGoogle Scholar
  • 101 Knoebl P, Sperr W, Schellongowski P. , et al. Emicizumab for the treatment of acquired hemophilia_A: lessons learned from 4 very different cases. Blood 2018; 132 (Suppl. 01) 2476
    CrossrefPubMedGoogle Scholar
  • 102 Knoebl P, Thaler J, Jilma-Stohlawetz P, Quehenberger P, Gleixner K, Sperr WR. Emicizumab for the treatment of acquired hemophilia A. Blood 2020 DOI: 10.1182/blood.2020006315
    CrossrefPubMedGoogle Scholar
  • 103 Weyand AC, Flood VH, Shavit JA, Pipe SW. Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies. Blood Adv 2019; 3 (18) 2748-2750
    CrossrefPubMedGoogle Scholar
  • 104 ICER. Emicizumab for hemophilia A with inhibitors: effectiveness and value. April 16, 2018. Available at: https://icer-review.org/wp-content/uploads/2017/08/ICER_Hemophilia_Final_Evidence_Report_041618.pdf . Accessed June 26, 2020
    PubMed
  • 105 Mahajerin A, Zhou Z-Y, Raimundo K. , et al. Model of short and long-term outcomes of emicizumab prophylaxis treatment for persons with hemophilia A. Blood 2018; 132 (Suppl. 01) 3511
    CrossrefPubMedGoogle Scholar
  • 106 Cortesi PA, Castaman G, Trifirò G. , et al. Cost-effectiveness and budget impact of emicizumab prophylaxis in haemophilia A patients with inhibitors. Thromb Haemost 2020; 120 (02) 216-228
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 107 Spadarella G, Di Minno A, Milan G. , et al. Paradigm shift for the treatment of hereditary haemophilia: towards precision medicine. Blood Rev 2020; 39: 100618
    CrossrefPubMedGoogle Scholar
  • 108 Peterson JA, Maroney SA, Mast AE. Targeting TFPI for hemophilia treatment. Thromb Res 2016; 141 (Suppl. 02) S28-S30
    CrossrefPubMedGoogle Scholar
  • 109 Chowdary P, Lethagen S, Friedrich U. , et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost 2015; 13 (05) 743-754
    CrossrefPubMedGoogle Scholar
  • 110 Pasi KJ, Rangarajan S, Georgiev P. , et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med 2017; 377 (09) 819-828
    CrossrefPubMedGoogle Scholar
  • 111 Rangarajan S, Walsh L, Lester W. , et al. AAV5-factor VIII gene transfer in severe hemophilia A. N Engl J Med 2017; 377 (26) 2519-2530
    CrossrefPubMedGoogle Scholar